BrightKaire Featured in DDN: First Blood Test to Personalize Antidepressant Treatment

For millions of people living with depression, finding an effective antidepressant often involves a lengthy process of trial and error. Drug Discovery News highlights how NeuroKaire is working to change that paradigm with BrightKaire™, the first blood test designed to help personalize antidepressant treatment.

In this feature, Drug Discovery News explores how BrightKaire combines patient-derived neurons with artificial intelligence to predict an individual's response to antidepressant medications before treatment begins. By providing clinicians with actionable biological insights, the technology aims to accelerate treatment decisions, reduce unnecessary medication switches, and improve outcomes for patients.

The coverage underscores the growing momentum behind precision psychiatry and NeuroKaire’s mission to bring more personalized, data-driven approaches to mental healthcare.

👉 Read the full article

‍